Australia’s First Egg Count Kit: Reproductive Health Update

August 2024 — News reports in Australia announced last month that women and their partners in the region are about to experience a revolutionary advancement in reproductive health. Thanks to a collaboration between WHEN Fertility and Trajan Scientific and Medical, Australian women can now take control of their reproductive health by collecting their own blood samples at home and mailing them to a lab for ovarian reserve (egg count) analysis.

Brett Barnes and Maz Coote, co-founders of WHEN Fertility, say it is important for women to understand their AMH status.

Launched in July 2024, the WHEN Fertility Egg Count Check is a kit that utilizes Trajan’s state-of-the-art Neoteryx^® Mitra^® device based on patented VAMS^® technology.

This innovative microsampling device enables easy and convenient finger-stick blood sample collection in the comfort of home.

With the test provided by an accredited lab working with WHEN Fertility, women can monitor their anti-Mullerian hormone (AMH) levels — a key indicator of ovarian reserve — without needing to visit a clinic.

The goal of this pioneering kit is to empower Australian women with the knowledge of their egg count status, providing them with a solid foundation before consulting with general practitioners and fertility specialists.

This approach allows women to take an active role in their reproductive health, making informed decisions with their healthcare providers about family planning.

Stephen Tomisich, CEO and Co-Founder of Trajan Scientific and Medical, highlights the importance of this collaboration with WHEN Fertility. He notes that the partnership aligns perfectly with Trajan’s mission to make healthcare more decentralized, personalized, and accessible.

“There’s a natural synergy between Trajan and WHEN — both companies share a commitment to making healthcare accessible and personalized,” Tomisich explained. “Our microsampling devices are already empowering people globally to collect their blood samples at home for accurate lab analysis. By partnering with WHEN Fertility, we’re now able to extend this technology to help Australians gain valuable insights into their reproductive health.”

WHEN Fertility, founded by Sydney-based couple Maz Coote and Brett Barnes, was born out of their personal fertility struggles.

Working alongside esteemed gynecologists and fertility specialists Professor William Ledger and Dr. Rachael Rodgers, WHEN Fertility aims to give others the information they need to navigate their reproductive health with confidence.

Professor Ledger, an internationally recognized expert, emphasizes that while egg count alone isn’t a complete measure of fertility, it can be a crucial early indicator. “By identifying women at risk of a depleted egg count earlier, we can help them explore their options and make informed decisions about their fertility journey,” said Ledger.

Dr. Rachael Rodgers, another leading figure in reproductive medicine, echoed these sentiments. “Egg count is one of the first things we assess in a patient’s fertility journey. Knowing this information upfront can make a significant difference in the decisions women make about their reproductive health,” Rodgers explained.

Once a woman collects her blood sample at home and sends it to the lab, it will be processed, and a confidential report will be generated. The results, overseen by Professor Ledger and Dr. Rodgers, will be delivered through WHEN’s secure digital platform.

For those with low results, a tele-education appointment with one of WHEN’s fertility nurses will be offered to ensure they fully understand the implications of their results.

This groundbreaking initiative marks a significant step forward in making reproductive health information more accessible, personalized, and actionable for women across Australia. With WHEN Fertility and Trajan Scientific and Medical leading the charge, the future of reproductive health is looking brighter than ever.

About Trajan
Trajan is a global developer and manufacturer of analytical and life sciences products and devices founded to enrich personal health through scientific tools and solutions. We aim to support science that benefits people. Trajan’s products and solutions are used in the analysis of biological, food, and environmental samples. Trajan has a portfolio and pipeline of new technologies which support the move towards decentralized and personalized data-based healthcare. Trajan comprises more than 600 people with several manufacturing sites across the US, Australia, Europe, and Malaysia, and operations in Australia, the US, Asia, and Europe. For more information, visit www.trajanscimed.com.

About WHEN
WHEN Fertility is a MedTech company that provides point-of-care testing supported with expert advice. Leveraging globally patented collection technology, WHEN’s at-home testing kits deliver NATA-accredited clinical grade results. By making this information more readily accessible, WHEN has a mission to help start the fertility conversation sooner, to give people more options later. Learn more at: www.whenfertility.com.au

This is a curated news story. Learn more by visiting the WHEN Fertility website.

Explore more of our microsampling stories via our Microsampling Blog. 

Image Credits: WHEN Fertility